Can a Two-Drug combo outsmart advanced cancers?
NCT ID NCT02718066
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers are looking at safety, tumor shrinkage, and how long the benefit might last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called HBI-8000 combined with the immunotherapy nivolumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial, so the combination may prove too toxic or no more effective than existing treatments. Side effects from both drugs could be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
[Site 01] Hematology - Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
[Site 02] Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
[Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc.
Tampa, Florida, 33612, United States
-
[Site 11] University of California, San Diego Medical Center
La Jolla, California, 92037, United States
-
[Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics
Houston, Texas, 77030, United States
-
[Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute
Frederick, Maryland, 21702, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?